Pharmaceuticals, Biotechnology and Life Sciences
Allergan plc has updated its second-half 2015 continuing operations financial forecast. The forecast reflects adjustments for the upcoming expected discontinued operations
Eli Lilly has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.
Phase II study of its Cyramza (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival (PFS) for patients with locally advanced or metastatic urothelial carcinoma who failed prior platinum-based therapy.
Collagen Solutions plc, has announced that its subsidiary Collagen Solutions Inc. has signed a supply agreement with Turkish medical device company Yücel Medikal Ltd.
Novartis has announced results of a Phase III pivotal study showing Afinitor (everolimus) tablets reduced the risk of progression by 52% vs placebo in patients with advanced, progressive, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin.
Allergan plc announced on Friday that it has launched a generic version of Janssen’s Invega (paliperidone extended-release tablets) in the…
Janssen-Cilag International NV has announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European…
The European Committee for Medicinal Products for Human Use (CHMP) has recommended Bayer’s aflibercept solution for injection into the eye…
Switzerland-based Novartis has today appointed Dr. James E. Bradner, physician-scientist from Dana-Farber Cancer Institute and Harvard Medical School, as President of the…
Novartis has announced the launch of Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and…